Key Facts Surrounding This News Item
- AST had returned -31.11% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.
More Info About Asterias Biotherapeutics, Inc. Common Series A (AST)
Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. The company was founded in 2012 and is based in Fremont, California. View our full AST ticker page with ratings, news, and more.